Investors are reaching for the riskiest stocks in the market.

How do we know?

A long list of stock market indexes and individual issues just had their best day since the pandemic lows almost 5 years ago.

Meme coins are mooning while we're asleep at night.

More and more stocks are completing primary trend reversals.

The most risk-on groups are leading the charge.

With this in mind, it's time for another Freshly Squeezed report.

Here's our approach:

We find the most heavily shorted stocks in the market. Then, we monitor these names for signs of upward momentum. Once that momentum kicks in, we ride them higher as the bears get squeezed.

We got fresh short data on Monday, so let's dive in and talk about it.

Our scan is quite simple. It is designed to identify stocks with the most aggressive short positions.

Despite being defensive, consumer stocks can make huge moves. 

Stocks like Monster Beverage, Celsius, and Sprouts Farmers Market are some of the best-performing names in recent history.

Today, we're outlining a consumer stock that rallied 300% in 6-months off its 2022 low. 

Since then, the stock has carved out a textbook accumulation pattern, which the market resolved last week following an earnings report.

With the short sellers caught offside, we're betting this breakout will spark a short squeeze and a fresh uptrend.

Let's get into the details:

The market keeps rewarding investors for buying some of Wall Street's most hated stocks. 

We're getting buy signals from biotechnology and crypto stocks, which tends to happen in healthy market environments.

With this in mind, we're going back to the well and buying a biotech stock with nearly 1/3 of the float sold short and a double-digit days-to-cover ratio. 

The stock we're buying is named after what was once an important ancient trade center in modern-day Turkey.

Let's talk about how we're playing this short squeeze:

From the Desk of Steve Strazza @Sstrazza

We all know how dreadful it can be to get through airport security.

Clear Secure is trying to be the remedy by using biometric data to provide identity verification and expedite security at airports and other venues.

Last quarter, the stock rallied over 20% following its earnings report and has nearly doubled since.

Despite the stock's strong performance and highest price since 2021, the bears are still betting against it. The amount of shares held short is near its highest level in history.

Let's talk about how we're playing it:

From the Desk of Steve Strazza @Sstrazza

What's better than a Bitcoin miner short squeeze?

Some of our best trades have come from these stocks as they can make dramatic moves in both directions.

Our crypto desk recently wrote "it appears this seven month bear market is reaching its concluding stages." 

With that in mind, what're we buying?

We're buying a leader in the crypto mining industry with a double-digit short interest and warrants to juice our returns even more.

Let's talk about it:
 

From the Desk of Steve Strazza @Sstrazza

The market keeps squeezing short sellers out of their biotech positions and rewarding bulls with big breakouts. 

Knowing this, our strategy is simple. We want to keep buying the best-looking and most heavily-shorted biotech stocks.

Today, we're covering one that has rallied nearly 200% since late last year. Despite this extreme upside momentum, the stock still has a massive short interest.

With the stock resolving a multi-year accumulation pattern, we think this short squeeze has plenty of room to run. To get back to the all-time highs from just a few years ago, it would require about a 10x.

We're looking for something much smaller and quicker for now, but you never know!

Let's talk about how we're trading our latest Freshly Squeezed setup.

When it comes to our short-squeeze universe, the best trades tend to come from the junkiest stocks. 

In late 2022, we went dumpster diving for the most beat-up and heavily shorted stocks in the market and had some big winners. We were at the depths of the bear cycle, and the charts looked terrible. They were supposed to be zeros, but they weren't.

Just look at how Carvana $CVNA has performed since we were buying it at 8.25 almost 2-years ago.

Another junky group that has been working recently is the Marine Shipper industry.

Our custom Marine Shipping Index is on the verge of reclaiming the 61.8% retracement of its prior drawdown:

From the Desk of Steve Strazza @Sstrazza

From the Desk of Steve Strazza @Sstrazza

Last week, we outlined a short squeeze in Phathom Pharmaceuticals $PHAT, which has been working for us.

It doesn't seem like the market is finished squeezing the short sellers out of their biotechnology positions.

Today, we're discussing yet another biotech stock that has a ridiculously high days-to-cover ratio and short interest.

More importantly, the risk couldn't be more well-defined.

So, we're stepping up to the plate and taking another swing at a short squeeze.

From the Desk of Steve Strazza @Sstrazza

Precious metals stocks have been ripping since Gold futures resolved a multi-decade accumulation pattern earlier this year.

But most of these stocks don't have much short interest...

We love to trade stocks with high short interest as there is a built in catalyst of forced buyers when the stock makes an upside move.

Today, we're outlining a trade for a precious metals stock with an extremely high days-to-cover ratio and short interest.

First, check out this long-term uptrend in A-Mark Precious Metals $AMRK:

From the Desk of Steve Strazza @Sstrazza

The biotech market has a great divide between the haves and have-nots. Some stocks have experienced tremendous markup phases, while others can't seem to get out of the doghouse.

Today, we're covering a biotech stock that has rallied nearly 200% this year. 

Despite this rally, the short sellers have continued to add to their positions and are close to carrying their largest short position ever.

With the stock coiling at a shelf of former highs from last summer, we're betting the short sellers are on the verge of unwinding their positions and sparking a short squeeze.

From the Desk of Steve Strazza @Sstrazza

The best short squeezes always start with a burst of momentum.

These moves are often sparked by a headline or news-related catalyst.

The price action in Peloton $PTON yesterday was an excellent example of this dynamic.

After reporting earnings Thursday, Peloton screamed higher and registered its best single-day performance in history.

While the report was nothing extra special, it was the first time the exercise bike maker beat on both the top and bottom line since May 2021.

When sentiment is this sour, sometimes "less bad" is all it takes.

PTON rallied 35% on the heels of the report, and with such a massive short interest, we think it's just getting started.

Here's the chart with the 1-day rate of change in the lower pane: